Stock comparison
Biogen
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BIIB
Biogen
Market cap
$28.61B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BIIB | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 53C | 65C | GMAB |
| Benjamin Graham | 63C | 64C | GMAB |
| Philip Fisher | 43D | 48D | GMAB |
| Peter Lynch | 21F | 25F | GMAB |
| Joel Greenblatt | 34F | 76B | GMAB |
| Charlie Munger | 48D | 68C | GMAB |
| Terry Smith | 49D | 71C | GMAB |
Side-by-side metrics
| Metric | BIIB | GMAB |
|---|---|---|
| Market cap | $28.61B | $16.5B |
| P/E (TTM) | 21.2x | 6.2x |
| EV/EBIT | 17.3x | 12.0x |
| ROIC (TTM) | 5.44% | 43.78% |
| Gross margin | 69.77% | 93.88% |
| Net margin | 13.92% | 18.23% |
| Revenue CAGR 5y | -2.78% | -18.45% |
| EPS CAGR 5y | -4.05% | -23.48% |
| Debt / Equity | 0.4x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BIIB leads on
- Revenue CAGR 5y-2.78%vs -18.45%+85%
- EPS CAGR 5y-4.05%vs -23.48%+83%
- Market cap$28.61Bvs $16.5B+42%
GMAB leads on
- ROIC (TTM)43.78%vs 5.44%+88%
- Debt / Equity0.1xvs 0.4x+79%
- P/E (TTM)6.2xvs 21.2x+71%
- EV/EBIT12.0xvs 17.3x+31%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.